奥图穆马
安慰剂
医学
不利影响
内科学
临床终点
入射(几何)
随机对照试验
胃肠病学
外科
病理
慢性淋巴细胞白血病
光学
物理
替代医学
白血病
作者
Jun‐ichi Kira,Jin Nakahara,Dmitry Sazonov,Takayoshi Kurosawa,Isao Tsumiyama,Roman Willi,Martin Zalesak,Ratnakar Pingili,Dieter A. Häring,Krishnan Ramanathan,Bernd C. Kieseier,Martin Merschhemke,Wendy Su,Takahiko Saida
标识
DOI:10.1177/13524585211055934
摘要
Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home.To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia.APOLITOS included a 24-week, double-blind, placebo-controlled core-part followed by an open-label extension-part. Patients were randomized (2:1) to subcutaneous ofatumumab 20 mg or placebo. Primary outcome was the number of gadolinium-enhancing (Gd+) T1 lesions per scan over 24 weeks.Sixty-four patients were randomized (ofatumumab, n = 43; placebo, n = 21). Primary endpoint was met; ofatumumab reduced Gd + T1 lesions versus placebo by 93.6% (p < 0.001) and the results were consistent across regions (Japan/Russia). Ofatumumab reduced annualized T2 lesion and relapse rate versus placebo by week 24. Both groups showed benefit from ofatumumab in the extension-part. Incidence of adverse events was lower with ofatumumab versus placebo (69.8% vs 81.0%); injection-related reactions were most common. No deaths, opportunistic infections, or malignancies were reported.Ofatumumab demonstrated superior efficacy versus placebo, with sustained effect through 48 weeks in RMS patients from Japan/Russia. Switching to ofatumumab after 24 weeks led to rapid radiological and clinical benefits. Safety findings were consistent with pivotal trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI